Evidence map›Paper›PMID 35793085›Full record

ArticleJAMA network open2022

Estimated Number of COVID-19 Infections, Hospitalizations, and Deaths Prevented Among Vaccinated Persons in the US, December 2020 to September 2021.

Molly K Steele, Alexia Couture, Carrie Reed, Danielle Iuliano, Michael Whitaker, Hannah Fast, Aron J Hall, Adam MacNeil, Betsy Cadwell, Kristin J Marks and 1 more

Open access · goldAbstract read
In one paragraph

Article in JAMA network open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed, 1 pooled it
21.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

82 citing papers in PubMed, 1 synthesis or guideline pooled it, 135 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

22 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Molly K SteeleCOVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, Georgia.
Alexia CoutureCOVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, Georgia.
Carrie ReedCOVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, Georgia.
Danielle IulianoCOVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, Georgia.
Michael WhitakerCOVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, Georgia.
Hannah FastCOVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, Georgia.
Aron J HallCOVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, Georgia.
Adam MacNeilCOVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, Georgia.
Betsy CadwellCOVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, Georgia.
Kristin J MarksCOVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, Georgia.
Benjamin J SilkCOVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, Georgia.
Centers for Disease Control and Prevention · USNational Center for Immunization and Respiratory Diseases · USUnited States Public Health Service · US

Funding

CDC HHS
6 · The paper itself

Abstract

Importance: The number of SARS-CoV-2 infections and COVID-19-associated hospitalizations and deaths prevented among vaccinated persons, independent of the effect of reduced transmission, is a key measure of vaccine impact. Objective: To estimate the number of SARS-CoV-2 infections and COVID-19-associated hospitalizations and deaths prevented among vaccinated adults in the US. Design, Setting, and Participants: In this modeling study, a multiplier model was used to extrapolate the number of SARS-CoV-2 infections and COVID-19-associated deaths from data on the number of COVID-19-associated hospitalizations stratified by state, month, and age group (18-49, 50-64, and ≥65 years) in the US from December 1, 2020, to September 30, 2021. These estimates were combined with data on vaccine coverage and effectiveness to estimate the risks of infections, hospitalizations, and deaths. Risks were applied to the US population 18 years or older to estimate the expected burden in that population without vaccination. The estimated burden in the US population 18 years or older given observed levels of vaccination was subtracted from the expected burden in the US population 18 years or older without vaccination (ie, counterfactual) to estimate the impact of vaccination among vaccinated persons. Exposures: Completion of the COVID-19 vaccination course, defined as 2 doses of messenger RNA (BNT162b2 or mRNA-1273) vaccines or 1 dose of JNJ-78436735 vaccine. Main Outcomes and Measures: Monthly numbers and percentages of SARS-CoV-2 infections and COVID-19-associated hospitalizations and deaths prevented were estimated among those who have been vaccinated in the US. Results: COVID-19 vaccination was estimated to prevent approximately 27 million (95% uncertainty interval [UI], 22 million to 34 million) infections, 1.6 million (95% UI, 1.4 million to 1.8 million) hospitalizations, and 235 000 (95% UI, 175 000-305 000) deaths in the US from December 1, 2020, to September 30, 2021, among vaccinated adults 18 years or older. From September 1 to September 30, 2021, vaccination was estimated to prevent 52% (95% UI, 45%-62%) of expected infections, 56% (95% UI, 52%-62%) of expected hospitalizations, and 58% (95% UI, 53%-63%) of expected deaths in adults 18 years or older. Conclusions and Relevance: These findings indicate that the US COVID-19 vaccination program prevented a substantial burden of morbidity and mortality through direct protection of vaccinated individuals.

Indexed as

COVID-19Influenza, HumanInfluenza VaccinesAd26COVS1AdultAgedBNT162 VaccineCOVID-19 VaccinesHospitalizationHumansSARS-CoV-2Ad26COVS1BNT162 VaccineCOVID-19 VaccinesInfluenza Vaccines

Identifiers

PMID35793085
PMCPMC9260489
OpenAlexW4284701209

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.